Gene therapy for sickle cell disease durability Authors: Chattip Prueksapraopong, Donald B. Kohn Published: 2026 TO THE EDITOR: We thank Naif Aljohani for his interest in our article, “Clinical outcomes of lentiviral vector gene therapy for sickle cell disease.” We appreciate his thoughtful comments regarding the terminology used to describe durability in sickle cell disease (SCD) gene therapy.1 We agree that gene marking and protein expression are distinct measures of therapeutic persistence. Gene marking, assessed by vector copy number in peripheral blood, provides evidence of long-term engraftment of gene-modified hematopoietic stem cells, whereas protein expression reflects functional transgene activity and is directly related to the therapeutic effect of the treatment. Therefore, in the authors’ opinion, durability should be defined by sustained clinical benefit, supported by persistent gene marking and continued transgene expression. We acknowledge that only 1 patient in our study demonstrated long-term persistence of both gene marking and transgene expression. One patient maintained gene marking but lost transgene expression, whereas 2 patients lost both gene marking and expression over time. These findings highlight the importance of evaluating both cellular persistence and functional gene expression when assessing long-term outcomes. Lentiviral vector gene therapy has demonstrated durable clinical benefit in other disease settings. In our previous clinical trials, sustained gene marking and transgene expression were observed in 50 patients with adenosine deaminase–deficient severe combined immunodeficiency2 and 9 patients with leukocyte adhesion deficiency type 1.3 However, patients with SCD have chronic bone marrow inflammation that may impair hematopoietic stem cell function and reduce the long-term survival of hematopoietic stem cells. These effects may influence engraftment and contribute to differences in durability compared with other disorders. Strategies to reduce inflammation, such as red blood cell transfusion or exchange transfusion before stem cell collection, along with other anti-inflammatory interventions, may improve clinical outcomes. We appreciate the opportunity to clarify this important issue. We agree that long-term follow-up and standardized definitions of durability will be important as gene therapy continues to advance. Conflict-of-interest disclosure: The authors declare no competing financial interests.